

=> d ibib abs ind hitstr l22 1-1

L22 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:753094 HCAPLUS
 DOCUMENT NUMBER: 131:346566
 TITLE: Use of **lipopeptides** or lipoproteins for wound treatment
 INVENTOR(S): Muehlradt, Peter; **Deiters, Ursula**
 PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung m.b.H. (GBF), Germany
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959610	A2	19991125	WO 1999-EP3436	19990519
WO 9959610	A3	20000120		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19822820	A1	19991125	DE 1998-19822820	19980520
CA 2328418	AA	19991125	CA 1999-2328418	19990519
AU 9942643	A1	19991206	AU 1999-42643	19990519
AU 756107	B2	20030102		
EP 1077717	A2	20010228	EP 1999-952073	19990519
EP 1077717	B1	20030723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002515446	T2	20020528	JP 2000-549274	19990519
AT 245433	E	20030815	AT 1999-952073	19990519
ES 2203193	T3	20040401	ES 1999-952073	19990519
US 2005192217	A1	20050901	US 2003-748033	20031230
PRIORITY APPLN. INFO.:				
			DE 1998-19822820	A 19980520
			WO 1999-EP3436	W 19990519
			US 2000-716778	B1 20001120

OTHER SOURCE(S): MARPAT 131:346566

AB A Mycoplasma **lipopeptide** or lipoprotein which on the N-terminus has a dihydroxypropylcysteine group with 2 possibly long-chain fatty acids linked by esterlike bonds is useful for treatment of **wounds** in humans or other animals. These **lipopeptides** and lipoproteins and their synthetic analogs stimulate the release of cytokines and prostaglandins by macrophages and induce high titers of chemokines in macrophages. The **lipopeptides** may be incorporated into liposomes or attached to a biodegradable carrier. Thus, synthetic R-MALP-2 [S-[2,3-bisphalmitoyloxy-(2R)-propyl]cysteiny-GNNDESNISFKEK] was incorporated into phospholipid-cholesterol liposomes which were resuspended in NaCl and injected i.p. into mice. The injection induced a marked migration of granulocytes and other leukocytes into the peritoneum. Intracutaneous injection of R-MALP-2 induced aggregation of leukocytes and formation of new tissue and blood vessels.

IC ICM A61K038-00

CC 1-12 (Pharmacology)

ST Mycoplasma **lipopeptide** leukocyte migration; chemotaxis leukocyte lipoprotein Mycoplasma; **wound healing lipopeptide** Mycoplasma

IT Drug delivery systems

(carriers; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(injections; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(liposomes; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(lotions; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(ointments; use of **lipopeptides** or lipoproteins for wound treatment)

IT Medical goods
(plasters; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(solns.; use of **lipopeptides** or lipoproteins for wound treatment)

IT Drug delivery systems
(suspensions; use of **lipopeptides** or lipoproteins for wound treatment)

IT Antiulcer agents
Burn
Chemotaxis
Leukocyte
Mycoplasma
Polymorphonuclear leukocyte
Wound healing promoters
(use of **lipopeptides** or lipoproteins for wound treatment)

IT **Lipopeptides**
Lipoproteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **lipopeptides** or lipoproteins for wound treatment)

IT 219986-22-8 250718-44-6 250718-45-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **lipopeptides** or lipoproteins for wound treatment)


IT 219986-22-8 250718-44-6 250718-45-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of **lipopeptides** or lipoproteins for wound treatment)

RN 219986-22-8 HCAPLUS


CN L-Lysine, S-[2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinyglycyl-L-asparaginyl-L-asparaginyl-L- α -aspartyl-L- α -glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L- α -glutamyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 250718-44-6 HCAPLUS


CN L-Lysine, S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L- α -aspartyl-L- α -glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L- α -glutamyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 250718-45-7 HCAPLUS
 CN L-Lysine, S-[(2S)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L- α -aspartyl-L- α -glutamyl-L-seryl-L-asparaginyl-L-isooleucyl-L-seryl-L-phenylalanyl-L-lysyl-L- α -glutamyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



=> d his

FILE 'HCAPLUS' ENTERED AT 16:31:36 ON 02 SEP 2006

L15 112 S L14
 E MUHLRADT PETER/AU
L16 19 S E2-4
 E DEITERS URSULA/AU
L17 5 S E3
L18 22 S L16 OR L17
L19 19 S L18 AND ?LIPOPEPTID?
L20 1 S L19 AND ?WOUND?
 SELECT RN L20 1

FILE 'REGISTRY' ENTERED AT 16:35:46 ON 02 SEP 2006

L21 3 S E1-3

FILE 'HCAPLUS' ENTERED AT 16:35:51 ON 02 SEP 2006

L22 1 S L20 AND L21